Intravacc and SynphaBase Conjugate Vaccine Partnership | Lucid Diligence Brief
Can Intravacc and SynphaBase create a streamlined synthetic glycan-to-GMP…
Vaccines Today—June 12, 2026
This weekly update in Vaccines and Immunization highlights key developments…
Why Lower Reactogenicity Alone Will Not Disrupt the Next-Generation Shingles Vaccine Market
AI-powered wargaming shows why lower reactogenicity may not disrupt the…
Public Health Today—May 29, 2026
This week’s public health update covers advances in cardiovascular and…
Vaccines Today—May 22, 2026
This weekly update covers recent developments in vaccine research, including…
Vaccines Today—May 15, 2026
This weekly vaccines update covers early-stage clinical progress, immunotherapy…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for pertussis vax
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for…
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…
Public Health Video Recap—December 19, 2025
This biweekly Public Health video recap highlights breakthroughs in vaccine…
How we supported a leading vaccine company in restructuring its global organization.
The Challenge: How to successfully lead restructuring in many geographies A…
RSV vaccines: A powerful tool to protect against RSV
According tο a recent systematic analysis focusing on children younger than…
